WT1 and acute myeloid leukemia: Conversely, a significant increase in OS was described between patients with WT1 > cut-off + NBC >0.5 (the category with the highest risk) treated with azacytidine plus venetoclax and the historical AML cohort (p = 0.0437) (Figure 3H).